Know Cancer

or
forgot password

A Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemo-naive, Advanced, Non-Small-Cell Lung Cancer Patients Aged 70 Years or Older in Taiwan


Phase 4
70 Years
N/A
Not Enrolling
Both
Non-Small Cell Lung Cancer

Thank you

Trial Information

A Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemo-naive, Advanced, Non-Small-Cell Lung Cancer Patients Aged 70 Years or Older in Taiwan


Inclusion Criteria:



- Adult patients, >=70 years of age

- Non-small cell lung cancer

- Naive to prior chemotherapy or specific immunotherapy

- Presence of at least 1 measurable lesion

Exclusion Criteria:

- Active non-controlled infection or disease

- CNS metastases

- Any other malignancies (other than adequately treated basal cell cancer of skin, or
in situ cancer of the cervix)

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Response rate (partial and complete response)

Outcome Time Frame:

From baseline up to 6 months

Safety Issue:

No

Principal Investigator

Clinical Trials

Investigator Role:

Study Chair

Investigator Affiliation:

Hoffmann-La Roche

Authority:

Taiwan: Department of Health

Study ID:

ML20322

NCT ID:

NCT01196078

Start Date:

February 2007

Completion Date:

December 2010

Related Keywords:

  • Non-Small Cell Lung Cancer
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location